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abstract
 
To determine whether protein tyrosine kinase (PTK) modulates volume-sensitive chloride current
(I
 
Cl.vol
 
) in human atrial myocytes and to identify the PTKs involved, we studied the effects of broad-spectrum and
selective PTK inhibitors and the protein tyrosine phosphatase (PTP) inhibitor orthovanadate (VO
 
4
 
 
 
3
 
). I
 
Cl.vol
 
evoked by hyposmotic bath solution (0.6-times isosmotic, 0.6T) was enhanced by genistein, a broad-spectrum PTK
inhibitor, in a concentration-dependent manner (EC
 
50
 
 
 
 
 
 22.4 
 
 
 
M); 100 
 
 
 
M genistein stimulated I
 
Cl.vol
 
 by 122.4 
 
 
 
10.6%. The genistein-stimulated current was inhibited by DIDS (4,4
 
 
 
-diisothiocyanostilbene-2,2
 
 
 
-disulfonic acid,
150 
 
 
 
M) and tamoxifen (20 
 
 
 
M), blockers of I
 
Cl.vol
 
. Moreover, the current augmented by genistein was volume de-
pendent; it was abolished by hyperosmotic shrinkage in 1.4T, and genistein did not activate Cl
 
 
 
 current in 1T. In
contrast to the stimulatory effects of genistein, 100 
 
 
 
M tyrphostin A23 (AG 18) and A25 (AG 82) inhibited I
 
Cl.vol
 
 by
38.2 
 
 
 
 4.9% and 40.9 
 
 
 
 3.4%, respectively. The inactive analogs, daidzein and tyrphostin A63 (AG 43), did not al-
ter I
 
Cl.vol
 
. In addition, the PTP inhibitor VO
 
4
 
 
 
3
 
 (1 mM) reduced I
 
Cl.vol
 
 by 53.5 
 
 
 
 4.5% (IC
 
50
 
 
 
 
 
 249.6 
 
 
 
M). Pretreat-
ment with VO
 
4
 
 
 
3
 
 antagonized genistein-induced augmentation and A23- or A25-induced suppression of I
 
Cl.vol
 
. Fur-
thermore, the selective Src-family PTK inhibitor PP2 (5 
 
 
 
M) stimulated I
 
Cl.vol
 
, mimicking genistein, whereas the se-
lective EGFR (ErbB-1) kinase inhibitor tyrphostin B56 (AG 556, 25 
 
 
 
M) reduced I
 
Cl.vol
 
, mimicking A23 and A25.
The effects of both PP2 and B56 also were substantially antagonized by pretreatment with VO
 
4
 
 
 
3
 
. The results sug-
gest that I
 
Cl.vol
 
 is regulated in part by the balance between PTK and PTP activity. Regulation is complex, however.
Src and EGFR kinases, distinct soluble and receptor-mediated PTK families, have opposing effects on I
 
Cl.vol
 
, and
multiple target proteins are likely to be involved.
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INTRODUCTION
 
A volume-sensitive chloride current, termed I
 
C1.vol
 
 or
I
 
Cl,swell
 
, is found in mammalian cardiac myocytes, in-
cluding those from man (for reviews see Hiraoka et al.,
1998; Sorota, 1999; Hume et al., 2000; Baumgarten and
Clemo, 2003). The current is activated by cell swelling
and/or membrane deformation. I
 
Cl.vol
 
 regulates cell
volume (Suleymanian et al., 1995), shortens action po-
tential duration (Vandenberg et al., 1997), and depo-
larizes resting membrane potential (Du and Sorota,
1997), suggesting that I
 
Cl.vol
 
 
 
may play a role in cardiac
electrophysiology and arrhythmogenesis in situ (Hira-
oka et al., 1998).
Multiple signaling pathways have been postulated to
control I
 
Cl.vol
 
 in cardiac (Sorota, 1999; Hume et al.,
2000; Baumgarten and Clemo, 2003) and noncardiac
tissues (Nilius et al., 1997). One of these, protein tyro-
sine kinase (PTK), is immediately activated upon myo-
cyte swelling (Sadoshima et al., 1996). Inhibitors of
PTK, such as the isoﬂavone genistein (Akiyama and
Ogawara, 1991) and several tyrphostins (Gazit et al.,
1989), and inhibitors of protein tyrosine phosphatase
(PTP), such as orthovanadate (VO
 
4
 
 
 
3
 
) (Gordon, 1991),
are widely used to identify regulation by tyrosine phos-
phorylation. Blocking PTKs with genistein inhibits I
 
Cl.vol
 
in dog atrial cells (Sorota, 1995), calf pulmonary artery
endothelial cells (Voets et al., 1998), and rabbit ciliary
epithelial cells (Shi et al., 2002). On the other hand,
PTP inhibitors also suppress I
 
Cl.vol
 
 in bovine chromaf-
ﬁn cells (Doroshenko, 1998) and mouse L-ﬁbroblasts
(Thoroed et al., 1999). These studies indicate that the
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phosphorylation and dephosphorylation of tyrosine
are involved in the modulation of I
 
Cl.vol
 
. Manipulations
with opposite consequences for tyrosine phosphoryla-
tion affected I
 
Cl.vol
 
 identically, however, suggesting regu-
lation may be tissue or species speciﬁc (Nilius et al.,
1997; Okada, 1997). Such diversity may arise because
tyrosine phosphorylation by speciﬁc PTKs controls dis-
tinct signaling cascades (Hunter, 1995; Pawson and
Scott, 1997; Zhang et al., 2002). Moreover, PTK inhibi-
tors previously have been shown to modulate both an-
ion (Sorota, 1995; Gadsby and Nairn, 1999) and cation
channels (Zhou et al., 1997) in heart and other tissues
(Davis et al., 2001).
Although we (Li et al., 1996) and others (Oz and So-
rota, 1995; Sakai et al., 1995; Sato and Koumi, 1998)
identiﬁed I
 
Cl.vol
 
 in human atrial myocytes, the modula-
tion of I
 
Cl.vol
 
 by signaling cascades is incompletely un-
derstood (Nilius et al., 1997; Sorota, 1999; Hume et al.,
2000) and may be species and tissue dependent (Nilius
et al., 1997; Okada, 1997). The present study demon-
strated that protein tyrosine phosphorylation and de-
phosphorylation regulate I
 
Cl.vol
 
 in human atrial myo-
cytes and that inhibition of Src family and epidermal
growth factor receptor (EGFR, ErbB-1) tyrosine kinases
have opposing effects.
 
MATERIALS AND METHODS
 
Cell Isolation
 
Atrial myocytes were isolated from specimens of right atrial ap-
pendage obtained from patients (50.1 
 
 
 
 8.2-yr-old, range, 35–
74) undergoing coronary artery bypass. Procedures for obtaining
the tissue with the patients’ written consent were approved by the
Ethics Committee of the University of Hong Kong. No evidence
for atrial arrhythmias or atrial dilation was found in any of the pa-
tients based on ECG and echocardiograms.
After excision, samples were quickly immersed in oxygenated,
nominally Ca
 
2
 
 
 
-free cardioplegic solution for transport to the
laboratory. Atrial myocytes were enzymatically dissociated by a
technique modiﬁed from that described previously (Li et al.,
1996). Brieﬂy, the myocardial tissue was sliced with a sharp blade,
placed in a 15-ml tube containing 10 ml of Ca
 
2
 
 
 
-free Tyrode solu-
tion (36
 
 
 
C), and gently agitated by continuous bubbling with
100% O
 
2
 
 for 15 min with transfer to fresh solution after 5 min.
Then, the chunks were incubated for 50 min in a similar solution
containing 150–200 U/ml collagenase (CLS II, Worthington Bio-
chemical), 1.2 U/ml protease (type XXIV, Sigma-Aldrich), and 1
mg/ml bovine serum albumin (Sigma-Aldrich). Finally, the tissue
was reincubated in a fresh enzyme solution without protease.
The number and the quality of the isolated cells were deter-
mined by microscopic examination at 5–10-min intervals. When
the yield appeared to be maximal, the tissue was suspended in a
high K
 
 
 
 medium and gently pipetted. The isolated myocytes
were kept at room temperature in the high K
 
 
 
 medium for at
least 1 h before study.
A small aliquot of the solution containing the isolated cells was
placed in an open perfusion chamber (1 ml) mounted on the
stage of an inverted microscope (Leica DM IL). Myocytes were al-
lowed to adhere to the bottom of the chamber for 5–10 min, and
were then superfused at 2–3 ml/min with isosmotic 1.0T (T,
times isosmotic), hyposmotic 0.6T or hyperosmotic 1.4T Tyrode
solution. Only quiescent rod-shaped cells showing clear cross-stri-
ations were used.
 
Solution and Drugs
 
Ca
 
2
 
 
 
-free cardioplegic solution for specimen transport contained
(in mM): 50 KH
 
2
 
PO
 
4
 
, 8 MgSO
 
4
 
, 5 adenosine, 10 HEPES, 140 glu-
cose, 100 mannitol, 10 taurine, pH was adjusted to 7.3 with KOH.
Standard Tyrode solution contained: 140 NaCl, 5.4 KCl, 1 MgCl
 
2
 
,
1.8 CaCl
 
2
 
, 0.33 NaH
 
2
 
PO
 
4
 
, 5 HEPES, 10 glucose, pH adjusted to
7.4 with NaOH. Ca
 
2
 
 
 
 was omitted from the Tyrode solutions used
for enzymatic digestion and for washing the sliced atrial tissue.
For osmotic swelling experiments, hyposmotic 0.6T (
 
 
 
180 mos-
mol/L) Tyrode was made by reducing NaCl from 140 to 80 mM,
and isosmotic 1T (
 
 
 
300 mosmol/L) and hyperosmotic 1.4T
(
 
 
 
420 mosmol/L) Tyrode were prepared by adding 125 or 240
mM mannitol, respectively, to 0.6T. The pipette solution con-
tained: 20 CsCl, 110 Cs-aspartate, 1.0 MgCl
 
2
 
, 10 HEPES, 5 EGTA,
0.1 GTP, 5 Na
 
2
 
-phosphocreatine, and 5 Mg-ATP, pH adjusted to
7.2 with CsOH (
 
 
 
295 mosmol/L). The high K
 
 
 
 storage medium
contained: 10 KCl, 120 K-glutamate, 10 KH
 
2
 
PO
 
4
 
, 1.8 MgSO
 
4
 
, 10
taurine, 10 HEPES, 0.5 EGTA, 20 glucose, 10 mannitol 10, pH
adjusted to 7.3 with KOH. All experiments were done at room
temperature, 21–22
 
 
 
C.
3-(4-Chlorophenyl)1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]py-
rimidin-4-amine (PP2) was purchased from Tocris. All other re-
agents were obtained from Sigma-Aldrich. Stock solutions were
made with DMSO for genistein (100–200 mM), daidzein (100
mM), tyrphostin A23 (AG 18), A25 (AG 82), A63 (AG 43), B56
(AG 556) (100 mM), and tamoxifen (20 mM). The stocks were di-
vided into aliquots and stored at 
 
 
 
20
 
 
 
C. The maximum 0.1%
ﬁnal concentration of DMSO in bath solution did not affect
I
 
Cl.vol
 
. Na
 
3
 
VO
 
4
 
 stock solution (1 M) was made with distilled water.
DIDS (4,4
 
 
 
-diisothiocyanostilbene-2,2
 
 
 
-disulfonic acid, 150 
 
 
 
M)
was freshly dissolved in the experimental solution.
 
Data Acquisition and Analysis
 
Whole-cell currents were recorded using an EPC-9 ampliﬁer and
Pulse software (Heka), and signals were low-pass ﬁltered (2 kHz)
before 5 kHz digitization. Pipette resistance was 2–3 M
 
 
 
, and
gigaseals were 
 
 
 
10 G
 
 
 
. Series resistance (3–8 M
 
 
 
) was compen-
sated (60–80%) after membrane rupture, and a 3-M KCl-agar
bridge was used as a reference electrode. In separate experi-
ments, the liquid junction potential (bath 
 
  
 
pipette) was mea-
sured as 
 
 
 
12 mV and was not corrected.
Relative cell volume was determined during the whole-cell re-
cording using each cell as its own control (Drewnowska and
Baumgarten, 1991). Images of myocytes were captured with a
digital camera (Leica DC300) at selected time points during the
experiment. Cell area and width were measured with commer-
cial software (Optimas, Media Cybernetics). Changes in cell
width and thickness are proportional. Taking each cell as its
own control, relative cell volume was calculated as vol
 
t
 
/vol
 
c
 
 
 
 
 
100 
 
 
 
 (area
 
t
 
 
 
 
 
 width
 
t
 
)/(area
 
c
 
 
 
 
 
 width
 
c
 
), where t and c refer to
test (e.g., 0.6T) and control (1T) solutions, respectively, and is
expressed as a percentage. The calculated values are indepen-
dent of assumptions regarding the geometric shape of the cross
section of the myocyte as long as the shape does not change.
These methods provide estimates of relative cell volume that
are reproducible to 
 
 
 
1% (Drewnowska and Baumgarten,
1991).
Nonlinear curve ﬁtting was performed using Pulseﬁt 8.53
(Heka) and SigmaPlot 8.01 (SPSS). Paired or unpaired Student’s
 
t
 
 tests were used as appropriate to evaluate differences between
two groups, and ANOVA was used for multiple groups (Sigma- 
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Stat 2.03, SPSS). P
 
 
 
  
 
0.05 was considered to indicate statistical
signiﬁcance. Results are presented as mean 
 
 
 
 SE.
 
RESULTS
 
Osmotic Swelling–induced Current
 
Fig. 1 A illustrates the time-course of swelling-induced
changes in membrane current at 
 
 50 mV in a human
atrial myocyte when bath solution was switched from
isosmotic 1T to hyposmotic 0.6T solution and then
back to 1T. Membrane current in 0.6T gradually in-
creased to a new steady-state within 15 min and fully re-
turned to control levels after reexposure to 1T. Similar
results were obtained in ﬁve cells. The swelling-induced
current is ICl.vol, as described previously (Li et al., 1996).
This was conﬁrmed by the application the ICl.vol blocker
DIDS (Sorota, 1999; Hume et al., 2000; Baumgarten
and Clemo, 2003). Fig. 1 B displays currents elicited
by voltage steps to between  100 and  60 mV from
 40 mV in 1T, 0.6T, and 0.6T with 150  M DIDS for 8
min, and Fig. 1 C shows the I-V relationships for the
swelling-induced current before and after exposure
to DIDS (n   6). The swelling-induced current out-
wardly rectiﬁed and reversed at  28 mV ( 40 mV af-
ter correction for the liquid junction potential), near
the predicted ECl,  35 mV. DIDS almost completely
inhibited the outward current, whereas inward cur-
rent was inhibited by  50%. These are characteristics
of ICl.vol and its voltage-dependent block by DIDS
(Sorota, 1999; Hume et al., 2000; Baumgarten and
Clemo, 2003).
Figure 1. ICl.vol in human atrial myocytes. (A) Time course of ac-
tivation of current at  50 mV on switching from isosmotic (1T) to
hyposmotic (0.6T) bath solution and full recovery in 1T. Currents
at time points a–c shown at right. Currents were elicited by 300-ms
steps to  50 from  40 mV (inset). (B) Voltage-dependent cur-
rents in 1T control (a), 0.6T (b), and 0.6T with 150  M DIDS (c).
DIDS, a blocker of ICl.vol, substantially inhibited the swelling-
induced current. Arrows indicate 0 current. Voltage protocol for B
and C, 300-ms steps to between  100 and  60 mV from  40 mV
(inset). (C) Current-voltage (I-V) relationships for 0.6T-induced
current ( ) and 0.6T-induced current with 150  M DIDS ( ); dif-
ference currents were obtained by subtracting the current in 1T
from that in 0.6T and 0.6T with DIDS. The 0.6T-induced current
was outwardly rectifying and was signiﬁcantly inhibited by DIDS at
test potentials from  100 to  50 mV and from  20 to  60 mV
(n   6, P   0.05 or P   0.01). Block by DIDS was greater at posi-
tive than negative voltages, as expected for ICl.vol.
Figure 2. Stimulation of ICl.vol by genistein. (A) Time course of
current at  50 mV. ICl.vol was elicited by switching from 1T (a) to
0.6T (b) bath solution. Cells then were exposed to 100  M
genistein in 0.6T (c), and genistein was washed out (d). Genistein
reversibly stimulated ICl.vol. Currents are shown at right. (B) Volt-
age-dependent current evoked in 1T control (a), 0.6T (b), and
0.6T with 100  M genistein (c). Arrows indicate 0 current. (C) I-V
relationships for ICl.vol ( ) obtained by subtraction of currents be-
fore and after 0.6T exposure, with genistein exposure ( ), and
drug washout ( ). *P   0.05; **P   0.01 vs. 0.6T. (D) Concentra-
tion-dependent stimulation of ICl.vol at  50 mV by genistein. EC50
was 22.4  M; number of cells at each concentration in parenthe-
ses. Voltage protocols are shown in insets.430 Modulation of Cardiac ICl.vol by Tyrosine Kinases
Effects of Genistein on ICl.vol
To study the effects of PTKs on ICl.vol, the broad-spectrum
PTK blocker genistein was applied after activating ICl.vol
by osmotic swelling. Fig. 2 A shows the time-course of
current at  50 mV as bathing solution was switched
from 1T, to 0.6T, and to 0.6T with 100  M genistein.
ICl.vol in 0.6T was signiﬁcantly enhanced by genistein, and
the stimulation was completely reversed upon washout.
Similar results were obtained in seven cells. Families of
currents obtained between  100 and  60 mV under the
same conditions are presented in Fig. 2 B. The I-V rela-
tionships showed that genistein reversibly increased the
amplitude of outwardly rectifying ICl.vol in 0.6T at test po-
tentials from  100 to  50 mV and from  10 to  60 mV
(Fig. 2 C; P   0.05 or P   0.01, n   7).
The concentration-response relationship for stimula-
tion of ICl.vol by genistein in 0.6T was evaluated at  50
mV (Fig. 2 D). Data were ﬁtted with the equation: E  
Emax [1   (EC50/C)b], where E is the stimulation of ICl.vol
in percent at concentration C, Emax is the maximum
stimulation, EC50 is the concentration for half-maximum
action, and b is the Hill coefﬁcient. The best-ﬁt parame-
ters were Emax   134.4%, EC50   22.4  M, and b   1.37.
To rule out possible nonspeciﬁc effects of genistein,
daidzein, an analogue of genistein that does not inhibit
PTK, was studied in ﬁve myocytes. Fig. 3 shows that
daidzein (100  M) did not affect the magnitude or the
time-independence of the current at  50 mV, whereas
genistein (100  M) reversibly stimulated the current by
 60% in the same myocyte. I-V relationships con-
ﬁrmed that daidzein did not affect ICl.vol over the en-
tire voltage range examined (Fig. 3 C) even though
genistein enhanced the current in each cell studied.
Effects of ICl.vol Blockers and Cell Volume on
Genistein-enhanced Current
To verify the identity of the genistein-induced increase
of Cl  current, DIDS and tamoxifen, which block ICl.vol
but not ICl.cAMP in heart (Vandenberg et al., 1994; So-
rota, 1999; Hume et al., 2000; Baumgarten and Clemo,
2003), were used. Currents were recorded in 1T, after
swelling in 0.6T, after stimulation of current by 100  M
genistein in 0.6T reached a steady-state, and after expo-
sure to ICl.vol blockers in 0.6T in the continued presence
of genistein. At  50 mV, DIDS (150  M) decreased the
Figure 3. Lack of effect of daidzein on ICl.vol. (A) Time course
of membrane current at  50 mV in 1T control (a), 0.6T (b),
0.6T with 100  M daidzein (c), 100  M genistein (d), and wash-
out of genistein (e). After ICl.vol reached a steady-state in 0.6T, it
was not signiﬁcantly affected by daidzein but was reversibly stimu-
lated by genistein. Protocol is shown in inset. (B) Currents at
time points a–e in A. Arrow indicates 0 current. (C) I-V relation-
ships for ICl.vol in absence ( ) and presence ( ) of 100  M daid-
zein (n   5, P   NS).
Figure 4. Tamoxifen blocks swelling- and genistein-induced cur-
rent. (A) Time course of membrane current at  50 mV. ICl.vol acti-
vated upon switching from 1T to 0.6T and was augmented by 100
 M genistein. Tamoxifen (20  M) substantially inhibited both the
swelling- and genistein-induced currents. Currents at time points
a–d at right. (B) Voltage-dependent currents in 1T control (a),
0.6T (b), 0.6T with 100  M genistein (c), and 0.6T with genistein
and 20  M tamoxifen. Both the 0.6T- and genistein-stimulated cur-
rents were outwardly rectifying. Arrows indicate 0 current. Voltage
protocols are shown in insets.431 Du et al. 
ICl.vol by 91.2   2.3% (n   4, unpublished data). In ad-
dition, tamoxifen (20  M) blocked  95% of the cur-
rent at   50 mV (n   3) in the continued presence of
genistein (Fig. 4). Thus, two structural distinct ICl.vol
blockers inhibited both the current augmented by
genistein and the current activated by cell swelling.
Another means of identifying the genistein-augmented
current is to examine its dependence on cell volume.
Genistein (100  M) did not alter membrane conduc-
tance when it was applied in 1T (n   5, unpublished
data). Furthermore, both the 0.6T- and genistein-depen-
dent activation of current promptly was reversed by
cell  shrinkage in 1.4T in the continued presence of
genistein (Fig. 5). Together, these data indicate that
genistein modulates a Cl  current that is turned on in
swollen myocytes and turned off by cell shrinkage.
Effect of Orthovanadate on ICl.vol
The PTP inhibitor VO4
 3 was used to determine
whether tyrosine dephosphorylation is involved in the
activation of ICl.vol in human atrial myocytes. Fig. 6 A
shows that VO4
 3 (1 mM) substantially inhibited ICl.vol
in 0.6T within 5 min, and the effect rapidly and fully re-
versed on washout. I-V relationships in the absence and
presence of VO4
 3 indicated that the current blocked
by VO4
 3 was outwardly rectifying and reversed near
the reversal potential for ICl.vol (Fig. 6 B; n   7). In con-
trast, VO4
 3 (1 mM) did not alter currents in 1T, con-
ﬁrming that the VO4
 3-sensitive current was ICl.vol (n  
5; unpublished data).
The concentration-response relationship for block of
ICl.vol by VO4
 3 at  50 mV is displayed in Fig. 6 C. Data
were ﬁtted as described above, except for inhibition.
The best-ﬁt parameters were Emax    49.5%, IC50   
249.6  M, and b   1.71.
Inﬂuence of Orthovanadate on Genistein
If stimulation of ICl.vol by genistein is due to block of ty-
rosine phosphorylation, inhibiting PTP-dependent ty-
rosine dephosphorylation should antagonize its effect.
A test of this prediction is illustrated in Fig. 7 A. At  50
mV, VO4
 3 signiﬁcantly reduced ICl.vol in 0.6T and sub-
stantially prevented stimulation of ICl.vol by genistein.
Figure 5. Cell shrinkage reversed swelling- and genistein-
induced activation of current. (A) Time course of membrane cur-
rent at  50 mV. After ICl.vol was activated by switching from 1T (a)
to 0.6T (b) and stimulated by 100  M genistein (c), bathing solu-
tion was switched to hyperosmotic 1.4T with genistein. Currents at
time points a–d are at right. (B) Voltage-dependent currents in 1T
control (a), 0.6T (b), 0.6T with 100  M genistein (c), and 1.4T
with genistein (d). Arrows indicate 0 current. Voltage protocols
are shown in insets.
Figure 6. Inhibition of ICl.vol by VO4
 3. (A) Time course of cur-
rent at  50 mV. ICl.vol was elicited by switching from 1T (a) to 0.6T
(b) bath solution. Cells then were exposed to 1 mM VO4
 3 (OV) in
0.6T (c), and VO4
 3 was washed out (d). VO4
 3 reversibly inhib-
ited ICl.vol. Currents are at right, and protocol is in inset. (B) I-V re-
lationships for ICl.vol induced by 0.6T ( ), with 1 mM VO4
 3 in
0.6T ( ), and after washout ( ). N   6, *P   0.05; **P   0.01 vs.
control ICl.vol. (C) Concentration-dependent inhibition of ICl.vol by
VO4
 3. IC50 was 249.6  M; number of cells in parentheses.432 Modulation of Cardiac ICl.vol by Tyrosine Kinases
Fig. 7 B illustrates families of ICl.vol obtained by subtract-
ing the current in 1T from those in 0.6T after the appli-
cation of 1 mM VO4
 3 alone or VO4
 3 with 100  M
genistein, and Fig. 7 C displays the I-V relationships of
ICl.vol after the addition of 1 mM VO4
 3 and VO4
 3 with
100   M genistein. Pretreatment with VO4
 3 signiﬁ-
cantly antagonized the genistein-induced increase of
ICl.vol over the entire voltage range studied as compared
with genistein alone (see Fig. 2). The results suggest
that regulation of ICl.vol depends at least in part on the
balance of tyrosine phosphorylation by PTKs and de-
phosphorylation by PTPs. Both genistein- and osmotic
swelling–induced stimulation of ICl.vol were opposed by
blocking dephosphorylation of tyrosine.
Selective Inhibition of Src
Although genistein is a broad-spectrum PTK inhibitor
that blocks both receptor and nonreceptor PTK, its
ED50 for stimulation of ICl.vol, 22.4  M (see Fig. 2 D) was
almost identical to its IC50 for block of pp60v-src, 25.9 or
29.6  M (Akiyama and Ogawara, 1991). This suggested
that inhibition of Src family PTKs might be responsible
the stimulation of ICl.vol. To test this hypothesis, we used
PP2, a selective inhibitor of Src family PTKs (Hanke et
al., 1996). Fig. 8 A shows ICl.vol in 0.6T before and after
application of 5  M PP2 and after its washout. PP2
gradually increased ICl.vol, reaching a steady-state after
10 min, and nearly complete recovery was obtained af-
ter a prolonged ( 30 min) washout of the drug. As pre-
viously shown for genistein (Fig. 6), stimulation of ICl.vol
by PP2 was antagonized by pretreatment with VO4
–3
(Fig. 8 B). At  50 mV, for example, PP2 increased ICl.vol
by 67.5   15.2% (n   9, P   0.01), whereas stimulation
Figure 7. VO4
 3 (OV) antagonized the stimulation of ICl.vol by
genistein. (A) Time course of current when order of exposure to
genistein and VO4
 3 was reversed; 1T control (a), 0.6T (b), 1 mM
VO4
 3 in 0.6T (c), and 100  M geneistein plus VO4
 3 (d). Pre-
treatment with VO4
 3 signiﬁcantly diminished stimulation of ICl.vol
by genistein. Currents are at right. (B) Voltage-dependent ICl.vol ob-
tained by digital subtraction of the current in 0.6T, after 1mM
VO4
 3, and VO4
 3 with 100  M genistein from that in 1T. (C) I-V
relationships of ICl.vol obtained by digital subtraction of currents be-
fore and after the application of VO4
 3 ( ), and VO4
 3 with 100
 M genistein ( ). Although pretreatment with VO4
 3 signiﬁcantly
reduced stimulation of ICl.vol by genistein (compare with Fig. 2; P  
0.01), a small but signiﬁcant stimulation was observed, 16.9   2.5
and 18.9   4.7% at  90 and  50 mV (P   0.01, n   7). Voltage
protocols are shown in insets.
Figure 8. Stimulation of ICl.vol by PP2. (A) Voltage-dependent ICl.vol
was obtained by digital subtraction of the current in 0.6T, 5  M
PP2 for 10 min, and washout of PP2 for 30 min from that in 1T.
Voltage protocols are shown in insets. (B) Voltage-dependent ICl.vol
in 0.6T, after 1 mM VO4
 3 (OV) for 5 min, and VO4
 3 with 5  M
PP2 for additional 10 min C. Histograms summarize effects of 5
 M PP2, 1 mM VO4
 3, and VO4
 3 plus 5  M PP2 on ICl.vol induced
by swelling in 0.6T. Pretreatment with VO4
 3 almost completely an-
tagonized the stimulation of ICl.vol by PP2.433 Du et al. 
by PP2 was not signiﬁcant, 2.2   7.1% (n   7, ns), after
pretreatment with 1 mM VO4
–3 (Fig. 8 C). These results
suggest that Src family PTKs play a role in the modula-
tion of ICl.vol in human atrial myocytes.
Effect of Tyrphostins on ICl.vol
Another important class of PTK inhibitors is the tyr-
phostins. To study effects of these nonisoﬂavone PTK
inhibitors on ICl.vol, tyrphostin A23 (100  M) was ap-
plied after activation of ICl.vol in 0.6T. In contrast to the
stimulatory effect of genistein and PP2, A23 reversibly
inhibited ICl.vol (Fig. 9 A). I-V relationships show that
A23 signiﬁcantly decreased the amplitude of ICl.vol at
test potentials from  100 to  50 mV and 0 to  60 mV
(n   7, P   0.05 or P   0.01; Fig. 9 B). The concentra-
tion-response relationship for inhibition of ICl.vol by A23
in 0.6T was evaluated at  50 mV (Fig. 9 C). Data were
ﬁtted with the Hill equation, and the concentration for
half maximum inhibition (IC50) of ICl.vol was 27.5  M,
and the Hill coefﬁcient was 0.71.
Another tyrphostin compound, A25, produced a sim-
ilar inhibition of ICl.vol as A23 (n    6, unpublished
data). To conﬁrm the tyrphostin-sensitive currents were
volume sensitive, A23 and A25 were studied in 1T. No
change in currents was observed (100  M, n   4 each;
unpublished data). Thus, tyrphostin PTK inhibitors,
which are structurally distinct from genistein and PP2,
produce the opposite effect on ICl.vol.
Tyrphostin A63, an inactive analogue of A23 and
A25, was examined to exclude nonspeciﬁc effects of tyr-
phostins on ICl.vol. ICl.vol was not affected by the applica-
tion of 100  M A63 for 8 min but was substantially re-
duced by 100  M A23 in the same cell (Fig. 10, A and
B). The I-V relationships conﬁrmed that A63 did not al-
ter ICl.vol over the entire voltage range studied (Fig. 10
C; n   5). The results suggest that suppression of ICl.vol
by tyrphostin A23 and A25 was related to inhibition of
tyrphostin-sensitive PTKs.
Inﬂuence of Orthovanadate on Tyrphostins
The effect of block of PTP on the modulation ICl.vol by
tyrphostin A23 is illustrated in Fig. 11. As shown previ-
ously (Fig. 6), VO4
 3 (1 mM) substantially inhibited ICl.vol
at  50 mV in 0.6T. After block of PTP by VO4
 3, A23
(100  M; Fig. 10 A) caused only a slight further suppres-
sion of ICl.vol. Fig. 11 C summarizes the data for A23. ICl.vol
Figure 9. Inhibition of ICl.vol by tyrphostin A23. (A) Time course
of current. ICl.vol was elicited by switching from 1T (a) to 0.6T (b)
bath solution. Cells then were exposed to 100  M A23 in 0.6T (c),
and tyrphostin was washed out (d). A23 reversibly inhibited ICl.vol.
Currents are at right, and protocol is in inset. (B) I-V relationships
for ICl.vol induced by 0.6T ( ), with 100  M A23 ( ), and after
washout of A23 ( ). *P   0.05; **P   0.01 vs. 0.6T-induced ICl.vol.
(C) Concentration-dependent inhibition of ICl.vol by A23. IC50 was
27.5  M; number of cells in parentheses.
Figure 10. Effect of tyrphostin A63 on ICl.vol. (A) Time course of
current at  50 mV. ICl.vol was elicited by switching from 1T (a) to
0.6T (b) bath solution. Cells then were exposed to 100  M A63 (c)
and 100  M A23 (d) in 0.6T. ICl.vol was not signiﬁcantly affected by
A63, an inactive analogue, but was blocked by A23 in the same cell.
Protocol in inset. (B) Currents at time points a–d in A. (C) I-V rela-
tionships for ICl.vol in absence ( ) and presence ( ) of 100  M
A63 (n   5, P   NS).434 Modulation of Cardiac ICl.vol by Tyrosine Kinases
was inhibited 38.3   4.2% by A23 (n   7, P   0.01; data
from Fig. 9 C), whereas 1 mM VO4
 3 inhibited ICl.vol by
48.0   5.9% (n   6, P   0.01). After pretreatment with
VO4
 3, A23 produced only a slight, 11.1   4.3%, but sig-
niﬁcant further decrease of ICl.vol (P    0.05,  n    6).
Thus, inhibition of ICl.vol by A23 was signiﬁcantly pre-
cluded by pretreatment with VO4
 3 (P   0.01).
Similarly, A25 inhibited ICl.vol by 41.0   3.4% (n   6,
P   0.01), whereas after pretreatment with VO4
–3, A25
decreased ICl.vol by only an additional 14.3   3.4% (n  
6, P   0.05). Thus, the inhibitory effect of A25 also was
signiﬁcantly precluded by VO4
 3 (P   0.01). The re-
sults suggest that the inhibition of ICl.vol by A23 and A25
depend on the balance between tyrosine phosphoryla-
tion and dephosphorylation.
Effects of Receptor–mediated PTK Inhibition on ICl.vol
Tyrphostin A23 and A25 are considered broad-spec-
trum PTK inhibitors, as is genistein, although potency
of these agents for speciﬁc PTKs varies. For example,
A23 is a more potent blocker of EGFR (ErbB-1) kinase
than of Src (Ramdas et al., 1994). This and the previous
results implicating Src in the stimulation of ICl.vol sug-
gested that inhibition of ICl.vol might be due to a recep-
tor-mediated PTK such as EGFR kinase. To test this hy-
pothesis, we used tyrphostin B56 (AG 556), a highly se-
lective inhibitor of EGFR kinase that does not block Src
family PTK (Gazit et al., 1991; Brenner et al., 1998).
Fig. 12 shows the effect of B56 at 10  M on ICl.vol in
0.6T. B56 reversibly suppressed ICl.vol (Fig. 12 A). Pre-
treatment with 1 mM VO4
 3 largely precluded a further
inhibition of ICl.vol by B56 (Fig. 12 B). Fig. 12 C summa-
rizes the data for B56 at  50 mV. ICl.vol was inhibited
72.6   3.1% by B56 (n   8, P   0.01), whereas 1 mM
VO4
 3 inhibited ICl.vol by 45.6   5.7% (n   9, P   0.01).
After pretreatment with VO4
 3, B56 produced a slight
but signiﬁcant further inhibition of ICl.vol, 9.9   5.3% of
ICl.vol in 0.6T (P   0.05 vs. after VO4
 3, n   9). The per-
cent reduction of ICl.vol by VO4
 3 plus B56, 54.4   6.5%,
was less than that with B56 alone, 72.6   3.1% (P  
0.01). Thus, selective inhibition of EGRF kinase by B56
and its interaction with VO4
 3 recapitulated the obser-
vations made with the broad-spectrum tyrphostins, A23
and A25.
Relative Cell Volume
To quantify the swelling of human atrial myocyte under
the present experimental conditions, relative cell vol-
ume was determined using each cell as its own control
while the cell was voltage clamped. Relative cell volume
increased in 0.6T to 132.4   2.5% of that in 1T (n  
25). Although genistein, VO4
 3, and tyrphostin A23
and A25 substantially modulated ICl.vol, they did not sig-
niﬁcantly affect relative cell volume. Relative cell vol-
ume was 134.3   3.4, 131.7   8.3, 133.6   5.7, and
135.6   4.2%, respectively, in the presence of 100  M
genistein, A23, or A25 or 1 mM VO4
 3 (n   4–7; P  
NS vs. 0.6T).
DISCUSSION
This study provides the ﬁrst evidence that ICl.vol in hu-
man atrial myocytes is regulated in part by the interplay
of PTK and PTP and that Src and EGFR kinases, dis-
tinct PTK families, have opposing effects ICl.vol. ICl.vol was
enhanced by the broad-spectrum isoﬂavone PTK inhib-
itor genistein and the selective Src family inhibitor PP2,
whereas broad-spectrum tyrphostin PTK inhibitors A23
and A25, and the highly selective EGFR kinase inhibi-
tor B56 diminished ICl.vol. ICl.vol also was suppressed by
the PTP inhibitor VO4
 3. Observations that isoﬂavone
Figure 11. VO4
 3 (OV) antagonized the inhibition of ICl.vol by
the tyrphostin A23. (A) Time course of current at  50 mV. ICl.vol
was elicited by switching from 1T (a) to 0.6T (b) bath solution.
Cells then were exposed to 1 mM VO4
 3 (OV, c) and VO4
 3 plus
100  M A23 (d) in 0.6T. Pretreatment with VO4
 3 signiﬁcantly di-
minished the block of ICl.vol by A23. Protocol is in inset. (B) Cur-
rents at time points a–d in A. (C) Histograms summarize effect of
100  M A23, 1 mM VO4
 3, and VO4
 3 plus 100  M A23 on ICl.vol in-
duced by swelling in 0.6T. **P   0.01 vs. 0.6T-induced ICl.vol; *P  
0.05 vs. 0.6T with VO4
 3; #P   0.01 vs. 0.6T with A23.435 Du et al. 
and tyrphostin PTK inhibitors modulate ICl.vol in oppo-
site directions imply that more than one PTK and more
than one tyrosine phosphorylation site contributes to
regulation of ICl.vol. Moreover, genistein did not stimu-
late ICl.vol in isosmotic 1T solution and did not maintain
the current after osmotic shrinkage in 1.4T. This sug-
gests that tyrosine phosphorylation modulates the ef-
fects of other signaling cascades rather than directly
controlling channel gating. Src and EGFR kinase are
well placed to be sensors of cell volume and mechani-
cal stretch. These signaling molecules interact with cy-
toskeleton, integral membrane proteins, and the sarco-
lemma, and tyrosine phosphorylation is among the ear-
liest responses to osmotic swelling in cardiac myocytes
(Sadoshima et al., 1996) and other cells (Tilly et al.,
1993).
Genistein, tyrphostins, and VO4
 3 are widely em-
ployed to ascertain whether PTKs and PTPs participate
in signaling cascades, but these agents also might act by
nonspeciﬁc mechanisms (Davis et al., 2001). Two lines
of evidence support the conclusion that PTK and
PTP inhibitors acted via phosphotyrosine in this study.
First, daidzein and tyrphostin A63, inactive analogs of
genistein and tyrphostins, respectively, were without ef-
fect. Second, as expected for phosphorylation-depen-
dent processes, inhibition of PTP by VO4
 3 countered
inhibition of PTK. This observation makes it unlikely
that genistein acted directly on the ICl.vol channel, for
example, by altering its volume set point. Alternatively,
one might argue that the tyrphostins A23, A25, and
B56 act as antioxidants (Sagara et al., 2002) rather
than PTK inhibitors. The antioxidant hypothesis does
not explain why VO4
 3 suppressed the action of tyr-
phostins, however. One also might posit that the VO4
 3
anion suppressed ICl.vol (e.g., Fig. 6) by blocking the Cl 
channel directly. This idea seems unlikely because the
fractional block of Cl  current by VO4
–3 strongly de-
pended on experimental conditions (1T vs. 0.6T; stim-
ulated by genistein or PP2 vs. inhibited by tyrphostin
A23, A25, or B56); if VO4
 3 simply blocked the pore,
fractional block should have been independent of in-
terventions that increased or decreased ICl.vol. More-
over, block by VO4
 3 did not appear to be voltage de-
pendent. On the other hand, because of its high afﬁn-
ity for phosphate binding sites, VO4
 3 interferes with
several phosphorylation-dependent processes besides
PTP. The possibility that nonspeciﬁc effects of PTK in-
hibitors and VO4
 3 contributed to the results cannot be
rigorously excluded.
Another concern is that genistein augments ICl,cAMP,
the CFTR current, in heart, cell lines, and expression
systems (Shuba et al., 1996; Zhou et al., 1998; Gadsby
and Nairn, 1999). This raises a question about the ori-
gin of the genistein-stimulated current. Identiﬁcation
of ICl.vol was based on biophysical and pharmacological
criteria, including outward rectiﬁcation, volume sensi-
tivity, reversal potential, and inhibition by DIDS and
tamoxifen, blockers of ICl.vol (Vandenberg et al., 1994;
Sorota, 1999; Hume et al., 2000; Baumgarten and
Clemo, 2003). ICl,cAMP can be confused with ICl.vol in cer-
tain situations but was ruled out here; cardiac ICl,cAMP is
insensitive to both DIDS and tamoxifen (Vandenberg
et al., 1994; Hume et al., 2000; Baumgarten and Clemo,
2003). Most workers agree that ICl,cAMP is not detectable
in human atrial myocytes (Oz and Sorota, 1995; Sakai
et al., 1995; Li et al., 1996; Sato and Koumi, 1998),
although one group reported ICl,cAMP in a fraction
( 20%) of human atrial cells and coexpression of
exon 5  and 5  splice variants of CFTR (Warth et al.,
1996). Moreover, genistein could not stimulate mem-
brane current under 1T conditions. Finally, contrary to
the present results, stimulation of ICl,cAMP by genistein is
not reversed by inhibiting PTP (Zhou et al., 1998;
Gadsby and Nairn, 1999). The Ca2 -activated Cl  cur-
Figure 12. Suppression of ICl.vol by B56. (A) Voltage-dependent
ICl.vol was obtained by digital subtraction of the current in 0.6T, 10
 M B56 for 10 min, and washout of B56 for 15 min from the cur-
rent in 1T. (B) Voltage-dependent ICl.vol in 0.6T, after 1 mM VO4
 3
(OV) for 5 min, and VO4
 3 with 10  M B56 for additional 10 min.
Protocol in inset. (C) Histograms summarize effects of 10  M B56,
1 mM VO4
 3, and VO4
 3 plus 10  M B56 on ICl.vol at  50 mV in-
duced by swelling in 0.6T (**P   0.01 vs. 0.6T-induced ICl.vol). Pre-
treatment with VO4
 3 signiﬁcantly antagonized the inhibition of
ICl.vol by B56 (**P   0.01 vs. B56, #P 0.05 vs. VO4
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rent, ICl,Ca (Hiraoka et al., 1998; Sorota, 1999; Hume et
al., 2000), also is unlikely to be responsible for the
present observations; it is a transient current and intra-
cellular Ca2  was well buffered here.
Regulation of ICl.vol by genistein-sensitive PTKs ap-
pears to be different in human atrial than in canine
atrial and rabbit ventricular myocytes. Sorota (1995) re-
ported that ICl.vol was inhibited by pretreatment with
50–80  M genistein and that acute application of tyr-
phostin A51, an EGFR kinase inhibitor, and herbimycin
A, a Src inhibitor, had no effect. ICl.vol activated by me-
chanical stretch also was suppressed by the acute appli-
cation of 100  M genistein or 10  M PP2 (Browe
and Baumgarten, 2003). It remains unclear, however,
whether these apparent differences in the regulation of
ICl.vol arise from the intrinsic characteristics of the cells
studied or experimental details such as the timing of
genistein exposure, means of activating ICl.vol, or tem-
perature at which the study was done. Furthermore, en-
hancement of 125I  efﬂux in cultured neonatal rat myo-
cytes by pervanadate has been attributed to inhibition
of PTP and activation of ICl.vol (Tilly et al., 1996), but
the efﬂux pathway was not identiﬁed by direct means.
Control of ICl.vol by Tyrosine Phosphorylation in Human Atria
The simplest explanation for the actions of genistein,
PP2, VO4
 3, and their interactions is that dephosphory-
lation of a critical tyrosine residue on the channel or
a signaling molecule directly or indirectly augments
ICl.vol. In this model (Fig. 13), inhibition of Src family
PTK by genistein or PP2 allows unopposed dephos-
phorylation of a tyrosine (Tyr1) by PTP, whereas inhibi-
tion of PTP blocks ICl.vol by allowing its unopposed
phosphorylation by the same PTK. This also explains
why pretreatment with VO4
 3 precluded the effect of
genistein and PP2. Once Tyr1 becomes phosphorylated
during VO4
 3 pretreatment, blocking PTKs will have lit-
tle effect because there is no efﬁcient means of dephos-
phorylating the residue. It is important to note, how-
ever, that genistein did not stimulate ICl.vol in 1T, and
stimulation of ICl.vol was reversed by osmotic shrinkage
in 1.4T. Thus, phosphorylation of the genistein-sensi-
tive site by Src does not appear to be sufﬁcient to acti-
vate or maintain ICl.vol in the face of contrary cell vol-
ume-dependent signaling. Such volume-dependent sig-
naling has been postulated to include one or more
Ser/Thr kinases (PKC, PKA, and MAPK) and phos-
phatases (Nilius et al., 1997; Sorota, 1999; Hume et al.,
2000), and the activity of Ser/Thr kinases and phos-
phatases are modulated by tyrosine phosphorylation
(Hunter, 1995; Pawson and Scott, 1997; Zhang et al.,
2002).
A second tyrphostin-sensitive PTK and a second phos-
phorylation site, Tyr2 (Fig. 13), also must be present
and regulate ICl.vol in the opposite manner as Tyr1
because ICl.vol was inhibited when EGFR kinase was
blocked by tyrphostin B56, A23, or A25. Recently, acti-
vation of ICl.vol by EGF peptides and inhibition by tyr-
phostin B46, an inhibitor of EGFR tyrosine kinase, was
reported in murine mammary C127 cells (Abdullaev et
al., 2003). The proposed involvement of EGFR kinase
in the regulation of cardiac ICl.vol does not necessarily
require the presence of its ligand, however. Transactiva-
tion of EGFR in myocytes and other types of cell can be
accomplished by multiple signaling molecules, oxi-
dants, and hyperosmotic shock (Zwick et al., 1999;
Shah and Catt, 2003). Moreover, EGFR activity is regu-
lated by autophosphorylation and Src-dependent tyro-
sine phosphorylation, and Src may act directly on
EGFR and downstream. Opposing effects of speciﬁc
PTK families on molecular and cellular function is a
known regulatory motif (Pawson and Scott, 1997; Yoon
et al., 1998; Zhang et al., 2002), but such dual regula-
tion has not been reported previously for ICl.vol or other
channels (Davis et al., 2001).
Although both Src and EGFR kinases regulate ICl.vol,
control by Src appeared to be dominant under present
conditions. The net effect of inhibiting PTP with VO4
 3
Figure 13. Schematic model of biphasic regulation of ICl.vol by
Src family and EGFR PTKs and PTPs. Two tyrosine phosphoryla-
tion sites, Tyr 1 and Tyr 2, on the ICl.vol channel or signaling mole-
cules are postulated. Tyr1 is phosphorylated by a PP2- and
genistein-sensitive Src family kinase and dephosphorylated by a
VO4
 3-sensitive PTP (PTPa). Phosphorylation of Tyr1 by one or
more steps (dashed line) favors ICl.vol channel closure, whereas de-
phosphorylation favors opening. Tyr2 is phosphorylated by tyr-
phostin-sensitive EGFR kinase and dephosphorylated by a VO4
 3-
sensitive PTP (PTPb). In contrast to Tyr1, phosphorylation of Tyr2
favors channel opening, whereas dephosphorylation favors clo-
sure. The effect of VO4
 3 on Tyr1 (thick lines) was dominant over
that on Tyr2 (thin lines). On the other hand, genistein did not ac-
tivate ICl.vol in 1T or maintain its activation after osmotic shrinkage
(thick solid lines). Therefore, tyrosine phosphorylation appears to
modulate channel activity rather than directly control gating.437 Du et al. 
was suppression of current, as expected from phos-
phorylation of Tyr1, rather than the stimulation ex-
pected from phosphorylation of Tyr2. The outcome of
inhibiting PTPs with opposing actions might reﬂect dif-
fering sensitivities of two PTPs to VO4
 3, differing basal
activities of Src and EGFR kinase, or the functional con-
sequences of phosphorylation at Tyr1 and Tyr2 and
their position in the signaling cascade. The effect of
temperature (21–22 C) on the balance between these
PTKs was not evaluated. Finally, our simpliﬁed model
assumes that inhibition of PTKs and PTPs are indepen-
dent. To the contrary, PTK positively regulates PTP and
PTP negatively regulates PTK in certain cases (Lam-
mers et al., 1993; Vogel et al., 1993).
Although genistein and both tyrphostin A23 and A25
are considered broad-spectrum PTK inhibitors, details
of their pharmacology support the conclusions reached
with the speciﬁc PTK inibitors, PP2 and B56. Genistein
binds to the ATP site on PTK and blocks pp60v-src with
an IC50 of 25.9 or 29.6  M (Akiyama and Ogawara,
1991). This is in good agreement with the EC50, 22.4  M,
for genistein-dependent stimulation of ICl.vol, and 100  M
genistein should substantially inhibit Src. This notion is
supported by the results with the Src family PTK inhibitor
PP2. On the other hand, A23 and A25 bind to the sub-
strate site (Gazit et al., 1989) and block Src with IC50s of
440 and 150  M, respectively (Ramdas et al., 1994). Thus,
only partial inhibition of Src should have occurred with
the 100  M tyrphostin A23 or A25 used here.
Regulation of ICl.vol by Tyrosine Phosphorylation
in Other Tissues
Consistent with the present results with genistein and
VO4
 3, inhibition of PTP, which favors tyrosine phos-
phorylation, blocks swelling-induced activation of ICl.vol
in bovine chromafﬁn cells (Doroshenko, 1998) and
mouse L-ﬁbroblasts (Thoroed et al., 1999). Genistein
and tyrphostin B46 do not alter ICl.vol in chromafﬁn
cells, however (Doroshenko, 1998).
Evidence in several systems indicates tyrosine phos-
phorylation can stimulate ICl.vol. Expression of p56lck, an
Src family PTK, was sufﬁcient to activate ICl.vol in human
T lymphocytes in the absence of swelling (Lepple-Wien-
hues et al., 1998). In ciliary epithelial cells, swelling-
induced ICl.vol was augmented by a peptide that binds to
the SH2 domain and up-regulates c-Src (Shi et al.,
2002). Moreover, PTK inhibitors suppress and PTP in-
hibitors stimulate ICl.vol in calf pulmonary artery endo-
thelial (Voets et al., 1998) and human prostate cancer
epithelial cells (Shuba et al., 2000). Finally, genistein
also blocks ICl.vol in rat astrocytes (Crepel et al., 1998).
Signiﬁcance
Regulation of ICl.vol by phosphorylation is variously re-
ported to depend on PKC, PKA, PTK, and MAPK in dif-
ferent cell types and species (Nilius et al., 1997; Sorota,
1999; Hume et al., 2000). Involvement of PTK was ﬁrst
proposed based on 125I  ﬂux studies in human intesti-
nal 407 cells (Tilly et al., 1993), and the present studies
establish the importance of tyrosine phosphorylation in
this process in human atrial cells. There are multiple
sites of cross-talk between PTKs and PTPs and the PKC,
PKA, and MAPK cascades (Baumgarten and Clemo,
2003), and each will need to be explored to fully under-
stand the regulation of ICl.vol in heart.
Both the molecular identity of ICl.vol and the signaling
systems responsible for its control are controversial (Ni-
lius et al., 1997; Okada, 1997; Sorota, 1999; Hume et
al., 2000; Jentsch et al., 2002). Some of the conﬂicts in
the literature might be rationalized if multiple distinct
molecules produce the current empirically deﬁned as
ICl.vol or if the volume sensor or regulatory signaling cas-
cades are tissue or species speciﬁc. Evidence for the
participation of multiple pore-forming molecules in-
cludes the widely varying unitary conductance of swell-
ing-activated Cl  channels; unitary conductance is 9.6
pS in human prostate (Shuba et al., 2000), 31 pS in
lymphocytes (Lepple-Wienhues et al., 1998), and 105
pS in ciliary epithelium (Zhang and Jacob, 1997).
Moreover, multiple swelling activated unitary Cl  cur-
rents are present in several cells (Banderali and Ehren-
feld, 1996; Zhang and Jacob, 1997). In rabbit atrial
myocytes, a DIDS-sensitive,  60-pS outwardly rectifying
channel was described (Duan and Nattel, 1994) and
a 28-pS channel was observed in other experiments
(Duan et al., 1997). In contrast, an 8.6-pS DIDS- and
stretch-sensitive Cl  channel was found in human atrial
myocytes (Sato and Koumi, 1998). Thus, it also is possi-
ble that multiple channel proteins controlled by dis-
tinct signaling pathways contribute to ICl.vol in heart.
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